Abstract
About this talk
The Major Histocompatibility Complex (MHC) is a large group of glycoproteins, categorized into various types, which function to selectively bind peptide fragments. MHC class I molecules present cancer-associated peptide antigens to CD8+ T lymphocytes, while CD4+ T lymphocytes recognize cancer antigens in the context of MHC class II molecules. Since the molecular composition of cancer antigens closely resembles that of self-antigens, they can be considered suitable candidates for cancer vaccination. Furthermore, cancer antigens play a central role in the induction of various T-helper cell subsets (such as Th1, Th2, Th17, etc.).
Today, through the use of bioinformatics, it is possible to identify numerous antigenic peptides that bind to HLA molecules and to devise effective strategies against cancer. CD8+ T lymphocytes play a significant and crucial role in the defense against cancer. By recognizing foreign peptides presented in the context of MHC molecules, these cells contribute to the elimination of cancer cells through the secretion of granzymes and perforin, as well as the surface expression of FASL. Therefore, this study aims to introduce methods for identifying immunogenic cancer peptides and inducing effective immune responses—in conjunction with HLA molecules—within experimental research, with the goal of opening new horizons in cancer treatment.
Speaker
About the speaker
